August 25, 2025 a 07:43 am
EW: Fundamental Ratio Analysis - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation operates in the healthcare sector, specializing in advanced medical technologies and solutions for structural heart diseases and critical care. Known for its innovation in transcatheter heart therapies, EW continues to show potential in both market reach and product development. Investors see this company as a reliable long-term investment given its steady growth and technological advancements.
Fundamental Rating
Edwards Lifesciences has displayed a solid fundamental performance, with a balanced score across major financial metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow (DCF) | 3 | |
| Return on Equity (ROE) | 5 | |
| Return on Assets (ROA) | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings (P/E) | 2 | |
| Price to Book (P/B) | 2 |
Historical Rating
The historical data shows stability in the company's scoring metrics, indicating consistent performance.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-22 | 4 | 3 | 5 | 5 | 3 | 2 | 2 |
| Previous Period | 0 | 3 | 5 | 5 | 3 | 2 | 2 |
Analyst Price Targets
Analyst estimates highlight a uniform consensus on the price target, emphasizing stable expectations.
| High | Low | Median | Consensus |
|---|---|---|---|
| 75 | 75 | 75 | 75 |
Analyst Sentiment
The prevailing sentiment among analysts is favorable, with a majority recommending 'Buy'.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 28 | |
| Hold | 19 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Edwards Lifesciences Corporation has demonstrated robust financial performance, making it a lucrative option for long-term investors. With steady ratings across key metrics and a strong buy consensus, the company shows resilience and growth potential. However, it is important for investors to monitor market conditions and technological shifts in the healthcare landscape. The company's focus on innovation positions it well for future success, yet competition and regulatory challenges inevitably pose risks. Overall, Edwards Lifesciences remains a well-regarded entity in the medical devices sector.